Navigation Links
APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
Date:2/24/2010

Leading medical centers in North America participate in study to evaluate the safety and efficacy of cyclosporine inhalation solution in preventing chronic rejection in lung transplant recipients.

Burlingame, CA (PRWEB) February 24, 2010 -- APT Pharmaceuticals, a specialty drug development company focused on the development of inhaled cyclosporine, announced today that it has completed enrollment in its Phase III CYCLIST trial. The multi-center, randomized, controlled study enrolled 288 recent lung transplant recipients across 19 leading centers in North America, including the Cleveland Clinic; the University of Pittsburgh; and the University of California, San Francisco.

The objective of the CYCLIST trial is to evaluate the safety and efficacy of cyclosporine inhalation solution in improving bronchiolitis obliterans syndrome (BOS)-free survival following lung transplantation. Lung transplantation is a life-saving procedure for people with end-stage lung diseases who have exhausted all other available treatment options. However, average survival post-lung transplant is less than five years -- significantly less than all other forms of solid organ transplant. Poor long-term outcomes in lung transplant patients appear to relate to BOS, a manifestation of chronic rejection, which remains a persistent problem despite administration of multi-drug systemic immunosuppressive regimens.

"We appreciate the broad support provided by the community of lung transplant centers, advocacy groups, patients and caregivers," said Dr. Charlie Johnson, chief medical officer of APT Pharmaceuticals. "They have exceeded our expectations by enrolling this trial in just ove
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... USA (PRWEB) March 29, 2015 A ... the United States and plenary talks by four leading ... SPIE Optics + Optoelectronics next month in Prague, ... presentations in 17 conferences alongside a two-day exhibition. Sponsored ... photonics , the event will run 13-16 April in ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an ... development by Shionogi & Co., Ltd., met its ... study (COMPOSE I) for the treatment of opioid-induced ... pain receiving opioid therapy. Study results showed that ... significantly improved the frequency of spontaneous bowel movement ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015 /PRNewswire/ ... 4901) ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: ... a leading developer and manufacturer of fully functioning human ... that the two companies have entered into a definitive ... tender offer to be followed by a second step ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
Breaking Biology Technology:Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
... (Nasdaq:,PPDI) today announced the appointment of Jose Luis ... lead the company,s delivery,of drug development services in ... City, Dr. Viramontes will provide overall management of ... brings a solid understanding of the pharmaceutical,industry in ...
... 27 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ) ... Markets Focus on Healthcare Conference on,Wednesday, December 5, 2007 ... in New York City., To access the live ... website at http://www.nastech.com approximately 15 minutes prior,to ...
... Innovations to Accelerate Workflow, CHICAGO, Nov. ... introduces the MAMMOMAT(R) Novation S, a new,digital ... for,screenings, at the 93rd Scientific Assembly and ... America (RSNA) from Nov. 25 to 30 ...
Cached Biology Technology:Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean 2Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean 3Siemens Unveils New Digital Mammography System for Optimized Screening 2
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... April 22, 2012) Researchers at Columbia University Medical ... the retention and release of the brain,s stem cells. ... neurologic development and could eventually lead to regenerative therapies ... collaborative effort of the laboratories of Drs. Anna Lasorella ...
... reductions in salt content and taxation on products containing salt ... each year from cardiovascular disease (CVD) by 2-3 per cent ... World Congress of Cardiology are the first findings from a ... year. The study set out to assess ...
... the Florida campus of The Scripps Research Institute has been ... Health to develop a range of new tests that could ... degenerative disorders of advancing age. Shuji Kishi, an assistant ... three-year study. The new tests will focus on diseases ...
Cached Biology News:'Housekeeping' mechanism for brain stem cells discovered 2'Housekeeping' mechanism for brain stem cells discovered 3Tax on salt could reduce cardiovascular disease deaths by 3 percent 2Researcher awarded $1 million for stress-associated disease and aging research 2
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... The Columbus is a flexible, fully automated microplate ... addition to its fully automated microplate strip washing ... performance and ease of operation. ... Columbus include manifolds of 8, 12 or 16 ...
... The Model 1575 immunowash microplate washer 100-240 ... that have flat-, U-, or V-bottom wells. ... horizontal and vertical needle positions to an ... crosswise aspiration, and overflow washing. It can ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
Biology Products: